Lasha Gogokhia, MD, MS

Lasha Gogokhia, MD, MSc, is an Assistant Professor of Medicine and Associate Director of Clinical Research in the Division of Gastroenterology and Hepatology at the Renaissance School of Medicine at Stony Brook University.

Dr. Gogokhia is a gastroenterologist with a focused clinical practice in inflammatory bowel disease, with expertise in the complex and multidisciplinary management of patients requiring coordinated medical, endoscopic, surgical, nutritional, and supportive care. He cares for patients with ulcerative colitis, Crohn’s disease, pouchitis, and complex colitis variants, including postoperative IBD management, dysplasia surveillance, and intestinal failure and malabsorption syndromes such as short bowel syndrome and bile acid diarrhea. His clinical expertise further includes microscopic colitis (lymphocytic and collagenous) and other immune-mediated gastrointestinal disorders, including immune checkpoint inhibitor–associated colitis (colitis related to cancer therapy), celiac disease, eosinophilic and lymphocytic gastroenteritis, cystic fibrosis–associated gut inflammation, and infectious complications such as Clostridioides difficile infection

Dr. Gogokhia completed his gastroenterology fellowship with advanced training in inflammatory bowel disease at Weill Cornell Medicine–NewYork Presbyterian Hospital in New York City, where he trained as a T32 research fellow and earned a Master’s degree in Clinical Investigation. His research focuses on translating emerging scientific discoveries into more individualized and effective care for patients with IBD. He studies why patients respond differently to therapies, how the gut microbiome and diet influence disease activity and treatment outcomes, and how biomarkers can be used to predict flares and guide more personalized and effective treatment decisions.

At Stony Brook, Dr. Gogokhia is a core faculty member in the Division of Gastroenterology and Hepatology and the Inflammatory Bowel Disease Center, where he is leading the development of an integrated IBD research program and biobank to advance precision medicine and improve long-term outcomes for patients with inflammatory bowel disease.

• Rahmani AR, Madani SA, Aminov E, Gogokhia L, Bench T, Kalogeropoulos A. Heart failure and cognitive impairment through the lens of the gut microbiome: a narrative review. Journal of Personalized Medicine. 2025;15(12). https://pubmed.ncbi.nlm.nih.gov/41440958/
• Gogokhia L, Tran N, Grier A, Nagayama M, Xiang G, Funez-dePagnier G, et al. Donor composition and fiber promote strain engraftment in a randomized controlled trial of fecal microbiota transplant for ulcerative colitis. Med. 2025;6(9):100707. https://pubmed.ncbi.nlm.nih.gov/40460824/
• Nagayama M, Gogokhia L, Longman RS. Precision microbiota therapy for IBD: premise and promise. Gut Microbes. 2025;17(1):2489067. https://pubmed.ncbi.nlm.nih.gov/40190259/
• Ying X, Gogokhia L, Jesudian AB, Zhang L, Crawford CV. Trends in Medicare spending and utilization of oral medications for Clostridioides difficile infection from 2013 to 2021. Gastroenterology and Hepatology Advances. 2024;3(2):210–211. https://pubmed.ncbi.nlm.nih.gov/39129961/
• Ahmed M, Islam M, Gogokhia L, Borz-Baba C, Wakefield D, Jakab SS. Hospital utilization for patients with cirrhosis and severe ascites in an outpatient paracentesis model. Cureus. 2023;15(12):e51397. https://pubmed.ncbi.nlm.nih.gov/38292997/
• Aydin Y, Gogokhia L, Ahmed SM, Turan SI, Shiferaw B. Rectal sunflower seed bezoar causing fecal impaction in a healthy young woman. Cureus. 2023;15(7):e42317. https://pubmed.ncbi.nlm.nih.gov/37614268/
• Gogokhia L, Lukin DJ. PRO tips: guidance for second-line therapy after TNF-alpha exposure in Crohn’s disease. Digestive Diseases and Sciences. 2023;68:3211–3212. https://pubmed.ncbi.nlm.nih.gov/37145193/
• Lima SF, Gogokhia L, Viladomiu M, et al. Transferable IgA-coated Odoribacter splanchnicus in responders to fecal microbiota transplantation for ulcerative colitis limits colonic inflammation. Gastroenterology. 2022;162:166–178. https://pubmed.ncbi.nlm.nih.gov/34606847/
• Gogokhia L, Round JL. Immune-bacteriophage interactions in inflammatory bowel disease. Current Opinion in Virology. 2021;49:30–35. https://pubmed.ncbi.nlm.nih.gov/34029992/
• Gogokhia L, Taur Y, Juluru K, et al. Intestinal dysbiosis and systemic inflammation in obese persons living with HIV. Journal of Acquired Immune Deficiency Syndromes. 2020;83:81–89. https://pubmed.ncbi.nlm.nih.gov/31809363/
• Gogokhia L, Buhrke K, Bell R, et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host & Microbe. 2019;25:285–299. https://pubmed.ncbi.nlm.nih.gov/30763538/
• Chiaro TR, Soto R, Stephens WZ, Kubinak JL, Petersen C, Gogokhia L, et al. A member of the gut mycobiota modulates host purine metabolism and exacerbates colitis. Science Translational Medicine. 2017;9:eaaf9044. https://pubmed.ncbi.nlm.nih.gov/28275154/
• Kubinak JL, Stephens WZ, Soto R, Petersen C, Chiaro T, Gogokhia L, et al. MHC variation shapes individualized microbial communities that control susceptibility to enteric infection. Nature Communications. 2015;6:8642. https://pubmed.ncbi.nlm.nih.gov/26494419/
• Leavitt JC, Gogokhia L, Gilcrease EB, et al. The tip of the tail needle affects DNA delivery by bacteriophage P22. PLoS One. 2013;8:e70936. https://pubmed.ncbi.nlm.nih.gov/23951045/
• Wolcott RD, Rhoads DD, Bennett ME, Wolcott BM, Gogokhia L, Costerton JW, Dowd SE. Chronic wounds and the medical biofilm paradigm. Journal of Wound Care. 2010;19:45–53. https://pubmed.ncbi.nlm.nih.gov/20216488/
• Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. Phage therapy in clinical practice: treatment of human infections. Current Pharmaceutical Biotechnology. 2010;11:69–86. https://pubmed.ncbi.nlm.nih.gov/20214609/